• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Epizootic Office/Food and Agriculture Organization fo the United Nations International Scientific Conference on Avian Influenza >Development of a Recombinant Fowlpox Virus Vector-Based Vaccine of H5N1 Subtype Avian Influenza
【24h】

Development of a Recombinant Fowlpox Virus Vector-Based Vaccine of H5N1 Subtype Avian Influenza

机译：研发H5N1亚型禽流感的重组禽病毒载体的疫苗

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The genetic stability of the recombinant fowlpox virus (named rFPV-HA-NA) was confirmed by serial passage on chicken embryo fibroblast (CEF) cells. The immune efficacy, safety, the minimum immunising dose, the time of immunity induced and the immune duration of the vector-based vaccine was evaluated in specific-pathogen-free (SPF) chickens. The recombinant virus vaccine containing 100 plaque form units (PFU) could induce complete protection against challenge with H5N1 highly pathogenic avian influenza virus (HPAIV). The immune efficacy, protecting chickens from clinical signs and death after challenge, was obtained one week after the immunisation with this vaccine. Protective immunity could last for 40 weeks post-immunisation. So the recombinant fowlpox vaccine is a safe and highly effective gene engineering vaccine candidate, and will be used to prevent H5 subtype avian influenza in the future.
机译：通过鸡胚胚胎成纤维细胞（CEF）细胞的连续通道证实了重组禽类病毒（命名RFPV-HA-Na）的遗传稳定性。在特异性病原体（SPF）鸡中评价免疫疗效，安全性，最小免疫剂量，诱导的免疫诱导的免疫时间和载体疫苗的免疫持续时间。含有100个斑块形式单位（PFU）的重组病毒疫苗可以对H5N1高致病性禽流感病毒（HPAIV）进行完全保护。在免疫接种疫苗后，在免疫后，在挑战后免受临床症状和死亡的免疫疗效，在免疫疗法后获得。保护性免疫可能持续40周后免疫后。因此，重组禽疫苗是一种安全且高效的基因工程疫苗候选，并将用于预防未来H5亚型禽流感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号